# Osavampator PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/osavampator

> The next catalyst for osavampator, sponsored by NEUROCRINE BIOSCIENCES INC (NBIX), is its interim data readout, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for osavampator?

The next catalyst for osavampator, sponsored by NEUROCRINE BIOSCIENCES INC (NBIX), is its interim data readout, 2027. SEC Form 10-K: "We have initiated a comprehensive Phase 3 clinical program for osavampator in MDD (with initial topline data expected in 2027), including three acute randomized, double-blind, placebo-controlled studies, a randomized-withdrawal maintenance-of-effect study, and a long-term open-label safety extension, reflecting our confidence in osavampator's potential to elevate the standard of care in MDD." [Calendar and source filings](https://sec-api.dev/pdufa/osavampator)

Source: SEC Form 10-K, accession 0000914475-26-000007, https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-02-11. Cite: https://sec-api.dev/pdufa/osavampator#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | osavampator |
| Codes | NBI-1065845 |
| Sponsor | NEUROCRINE BIOSCIENCES INC (NBIX) https://sec-api.dev/companies/nbix/catalysts |
| Indications | [major depressive disorder](https://sec-api.dev/indications/major-depressive-disorder) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Apr 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2. Indication: major depressive disorder.
- First seen 2025-02-10, last confirmed 2025-02-10.
- SEC Form 10-K (accession 0000914475-25-000037): "In April 2024, we announced positive top-line data from the Phase 2 SAVITRI™ study of osavampator in adults with major depressive disorder." https://www.sec.gov/Archives/edgar/data/914475/000091447525000037/nbix-20241231.htm

### 2027: interim data readout

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2026-02-11, last confirmed 2026-02-11.
- SEC Form 10-K (accession 0000914475-26-000007): "We have initiated a comprehensive Phase 3 clinical program for osavampator in MDD (with initial topline data expected in 2027), including three acute randomized, double-blind, placebo-controlled studies, a randomized-withdrawal maintenance-of-effect study, and a long-term open-label safety extension, reflecting our confidence in osavampator's potential to elevate the standard of care in MDD." https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/nbix-20251231.htm

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Major Depressive Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07196501 (A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." https://clinicaltrials.gov/study/NCT07196501

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Major Depressive Disorder.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07196501 (A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Neurocrine Biosciences." https://clinicaltrials.gov/study/NCT07196501

## Same indication

- [ACP-211](https://sec-api.dev/pdufa/acp-211) (ACAD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/osavampator.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Osavampator PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/osavampator

```bibtex
@misc{secapidev_pdufa_osavampator_20261116,
  title        = {Osavampator PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/osavampator}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_osavampator_20261116","title":"Osavampator PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/osavampator","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
